Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: March 2008
-
By Christopher P. Singer — IpAuctions, Inc. recently announced that it will seek to sell U.S. Patent No. 6,645,525, which relates to drug delivery technology. The patent is titled "Ionically Formulated Biomolecule Microcarriers," and is assigned to Sedum Laboratories, Inc. The technology, called "Bi-Acervation" which can encapsulate, stabilize, and provide sustained release of…
-
By Kevin E. Noonan — The patent community got its biggest scare in quite a while late last year, when a rules package thought to be dead for almost a year was released on August 21, 2007 (see "New Continuation and Claims Rules Published"). And even then, initially the only member of our…
-
By Kevin E. Noonan — The two remaining ex parte re-examinations (35 U.S.C. § 302-307) of Wisconsin Alumni Research Foundation (WARF) stem cell patents — Control No. 90/008102 for U.S. Patent No. 5,843,780 (claiming primate embryonic stem (pES) cells) and Control No. 90/008139 for U.S. Patent No. 6,200,806 (claiming human embryonic stem cell…
-
By Donald Zuhn — As we reported yesterday, the U.S. Patent and Trademark Office published a Notice in the Federal Register on Monday supplementing to its Alternative Claims Notice of Proposed Rule Making from last August. According to the Patent Office, the supplementary Notice was published in response to comments to the first…
-
By Kevin E. Noonan — Any hopes that Thailand would amend or overrule its policy of ignoring drug patent rights were dashed when the Thai government announced that it intended to maintain its extension of its compulsory licensing policy to four anti-cancer drugs: Novartis' Imatinib® and Letrozole®, Sanofi-Aventis' Docetaxel®, and Roche's Erlotinib®. The…
-
By Brad Crawford — As we previously reported, on December 14, 2007, the Administrative Council of the European Patent Organization increased the amounts of various fees that patent applicants are required to pay. The Council’s decisions can be found here and here. We summarize the changes to the claim fees below, and provide…
-
By Kevin E. Noonan — On Friday, the Court of Appeals for the Federal Circuit handed Pfizer a mixed decision on defendant Teva’s appeal of a District Court judgment that Teva was liable for infringing a trio of Pfizer patents (U.S. Patent Nos. 5,466,823; 5,563,165; and 5,760,068) relating to the pain medication Celebrex®…
-
By Christopher P. Singer — As we reported on Friday, the U.S. Patent and Trademark Office published a "Proposed Rules" Notice entitled "Examination of Patent Applications That Include Claims Containing Alternative Language," (Markush claims) in the March 10, 2008 Federal Register. The Notice did not enact any Final Rule change, but rather provided…
-
By Donald Zuhn — On February 28th, the Federal Circuit, in Regents of the Univ. of California v. DakoCytomation California, Inc.: (a) affirmed the denial by the District Court for the Northern District of California of a preliminary injunction sought by the Regents of the University of California, Abbott Molecular Inc., and Abbott…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Duramed Pharmaceuticals, Inc. v. Watson Laboratories, Inc. et al.3:08-cv-00116; filed March 6, 2008 in the District Court of Nevada Duramed Pharmaceuticals, Inc.…
Patent Docs 